propafenone

FDA Drug Profile — Propafenone Hydrochloride

propafenone is listed in the FDA National Drug Code directory with 3 NDC codes, marketed under brand name including Propafenone Hydrochloride. Available dosage form: capsule, extended release.

Drug details

Generic Name
propafenone
Brand Names
Propafenone Hydrochloride
Application Number
ANDA210339
Sponsor
Vitruvias Therapeutics
NDC Codes
3
Dosage Forms
CAPSULE, EXTENDED RELEASE
Routes
ORAL
Active Ingredients
PROPAFENONE HYDROCHLORIDE

Indications and Usage

1 INDICATIONS AND USAGE Propafenone hydrochloride extended-release capsules is indicated to prolong the time to recurrence of symptomatic atrial fibrillation (AF) in patients with episodic (most likely paroxysmal or persistent) AF who do not have structural heart disease. Usage Considerations: The use of propafenone hydrochloride extended-release capsules in patients with permanent AF or in patients exclusively with atrial flutter or paroxysmal supraventricular tachycardia (PSVT) has not been evaluated. Do not use propafenone hydrochloride extended-release capsules to control ventricular rate during AF. Some patients with atrial flutter treated with propafenone have developed 1:1 conduction, producing an increase in ventricular rate. Concomitant treatment with drugs that increase the functional atrioventricular (AV) nodal refractory period is recommended. The effect of propafenone on mortality has not been determined [see Boxed Warning] . Propafenone hydrochloride extended-release capsules is an antiarrhythmic indicated to prolong the time to recurrence of symptomatic atrial fibrillation (AF) in patients with episodic (most likely paroxysmal or persistent) AF who do not have structural heart disease. (1) Usage Considerations: Use in patients with permanent atrial fibrillation or with atrial flutter or paroxysmal supraventricular tachycardia (PSVT) has not been evaluated. Do not use to control ventricular rate during atrial fibrillation. (1) In patients with atrial fibrillation and atrial flutter, use propafenone hydrochloride extended-release capsules with drugs that increase the atrioventricular nodal refractory period. (1) The effect of propafenone on mortality has not been determined. (1)

Sources: openFDA, FDA Data Dashboard, FDA.gov. Report a data issue: hello@regdatalab.com.